Therapeutic Vaccines for Prostate Cancer

Cancer Statistics, 2005

2005 • 5,487 citations

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

2004 • 5,439 citations

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

2004 • 3,606 citations

Natural History of Progression After PSA Elevation Following Radical Prostatectomy

1999 • 2,993 citations

IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE

1973 • 2,286 citations

Dendritic Cells

2001 • 2,164 citations

Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis.

1981 • 1,281 citations

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

2005 • 997 citations

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

1999 • 994 citations

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.

1996 • 922 citations

Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

1999 • 907 citations

Differential Requirements for Survival and Proliferation of CD8 Naïve or Memory T Cells

1997 • 875 citations

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma

1998 • 638 citations

Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells

2000 • 627 citations

Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes

2004 • 532 citations

Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro.

1979 • 514 citations

Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

1995 • 506 citations

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

2002 • 491 citations

Phase I Trial of ¹⁷⁷Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer

2005 • 486 citations

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

1999 • 468 citations

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

2001 • 454 citations

Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy

2003 • 452 citations

NK susceptibility varies inversely with target cell class I HLA antigen expression.

1987 • 433 citations

External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing

2004 • 425 citations

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

2002 • 424 citations

Limiting dilution assays for the determination of immunocompetent cell frequencies.

1981 • 386 citations

Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

2005 • 373 citations

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

2001 • 373 citations

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial

2003 • 368 citations

Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses

2000 • 363 citations

Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

2004 • 353 citations

Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer

2005 • 352 citations

Phase I Trial of Yttrium-90—Labeled Anti—Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer

2004 • 310 citations

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

2000 • 300 citations

Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

2004 • 298 citations

A triad of costimulatory molecules synergize to amplify T-cell activation.

1999 • 293 citations

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

2006 • 291 citations

Homeostatic T Cell Proliferation

2000 • 279 citations

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen

2005 • 279 citations

The First 1000 Dendritic Cell Vaccinees

2003 • 277 citations

Radical Prostatectomy for Clinical Stage T1-2N0M0 Prostatic Adenocarcinoma: Long-Term Results

1990 • 274 citations

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

1997 • 269 citations

Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?

1995 • 264 citations

Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group

2004 • 252 citations

Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential

2005 • 239 citations

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer

2002 • 230 citations

The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2.

1991 • 214 citations

Demonstration of a Rational Strategy for Human Prostate Cancer Gene Therapy

1994 • 210 citations

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

1997 • 209 citations

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

1999 • 206 citations

Immune Modulation by Ionizing Radiation and its Implications for Cancer Immunotherapy

2002 • 200 citations

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

2001 • 198 citations

Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial

2004 • 187 citations

PROSTATE CANCER IS HIGHLY PREDICTABLE: A PROGNOSTIC EQUATION BASED ON ALL MORPHOLOGICAL VARIABLES IN RADICAL PROSTATECTOMY SPECIMENS

2000 • 182 citations

Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.

1994 • 181 citations

Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.

1996 • 180 citations

A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.

1999 • 177 citations

Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.

1994 • 166 citations

Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial.

2000 • 164 citations

The immunological effects of taxanes

2000 • 149 citations

PROSTATE SPECIFIC ANTIGEN DOUBLING TIME AS A SURROGATE END POINT FOR PROSTATE CANCER SPECIFIC MORTALITY FOLLOWING RADICAL PROSTATECTOMY OR RADIATION THERAPY

2004 • 148 citations

Follow-up evaluation of a phase II prostate cancer vaccine trial

1999 • 147 citations

Multiple Costimulatory Modalities Enhance CTL Avidity

2005 • 145 citations

Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.

2001 • 137 citations

Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer

1997 • 134 citations

Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells

1992 • 132 citations

Delayed Disease Progression after Allogeneic Cell Vaccination in Hormone-Resistant Prostate Cancer and Correlation with Immunologic Variables

2005 • 129 citations

Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer

2005 • 116 citations

ANTIANDROGEN, VACCINE AND COMBINATION THERAPY IN PATIENTS WITH NONMETASTATIC HORMONE REFRACTORY PROSTATE CANCER

2005 • 112 citations

MHC class I is required for peripheral accumulation of CD8+ thymic emigrants.

1998 • 112 citations

Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate‐pulsed cells: a phase I/II study

2004 • 109 citations

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

1995 • 109 citations

MHC Class I Is Required for Peripheral Accumulation of CD8+ Thymic Emigrants

1998 • 100 citations

Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells

2005 • 88 citations

Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival

2001 • 87 citations

Mutations in the alpha 2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide.

1988 • 83 citations

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA

2004 • 79 citations

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

2000 • 79 citations

HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma.

1995 • 72 citations

Allogeneic whole‐cell vaccine: a phase I/II study in men with hormone‐refractory prostate cancer

2002 • 71 citations

Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients

2000 • 70 citations

Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15—the Amplispot assay

2002 • 69 citations

Ionizing Radiation Alters Fas Antigen Ligand at the Cell Surface and on Exfoliated Plasma Membrane-Derived Vesicles: Implications for Apoptosis and Intercellular Signaling

2000 • 69 citations

DENDRITIC CELL BASED VACCINES: PROGRESS IN IMMUNOTHERAPY STUDIES FOR PROSTATE CANCER

2004 • 55 citations

Interleukin‐2 transfected prostate cancer cells generate a local antitumor effect in vivo

1994 • 45 citations

The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.

2001 • 42 citations

Anti-tyrosinase antibodies in malignant melanoma

1996 • 36 citations

Therapeutic Effects of Tumor Reactive CD4+ Cells Generated From Tumor-Primed Lymph Nodes Using Anti-CD3/Anti-CD28 Monoclonal Antibodies

2002 • 33 citations

Prostate‐specific antigen velocity and survival for patients with hormone‐refractory metastatic prostate carcinoma

2005 • 31 citations

Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer

2005 • 30 citations

Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: Follow-up clinical results from ECOG 7897

2005 • 30 citations

Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer (HRPC)

2005 • 30 citations

A phase II study of PROSTVAC-VF vaccine, and the role o f GM-CSF, in patients (pts) with metastatic androgen insensitive prostate cancer (AIPC)

2005 • 28 citations

Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (met HPRC)

2005 • 21 citations

A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer

2001 • 18 citations

Prevention of de novo prostate cancer by immunization with tumor-derived vaccines

2005 • 17 citations

Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy

2005 • 13 citations

Atlas of Clinical Urology

2000 • 12 citations

Management of metastatic prostate cancer

1998 • 11 citations

A phase I study of sequential vaccinations with recombinant Fowlpox-PSA (L155)-TRICOM (rF)alone, or in combination with recombinant vaccinia-PSA (L155)-TRICOM (rV), and the role of GM-CSF, in patients (Pts) with prostate cancer

2004 • 10 citations

350. Phase II Trials of a GM-CSF Gene-Transduced Prostate Cancer Cell Line Vaccine (GVAX) in Hormone Refractory Prostate Cancer

2002 • 9 citations

DC therapy for prostate cancer

2004 • 8 citations

Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5‐fluorocytosine suicide‐gene therapy

2005 • 6 citations